Profile: La Jolla Pharmaceutical Co (LJPC.A)
24 May 2019
La Jolla Pharmaceutical Company, incorporated on May 8, 2012, is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. It has several product candidates in development. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH). It is developing LJPC-401 for the potential treatment of iron overload. LJPC-30S is its next-generation gentamicin derivative program.
The Company has initiated a Phase III trial of LJPC-501 for the treatment of CRH, called the Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS) Phase III trial. As of December 31, 2016, the ATHOS 3 Phase III trial completed enrollment of over 340 patients. LJPC-401 is its formulation of synthetic human hepcidin for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. LJPC-30S is its next-generation gentamicin derivative program that is focused on therapeutics for the potential treatment of serious bacterial infections, as well as rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.
La Jolla Pharmaceutical Co
4550 Towne Centre Ct
SAN DIEGO CA 92121-1900